| Year |
Citation |
Score |
| 2024 |
Olivieri DJ, Othus M, Orvain C, Rodríguez-Arbolí E, Milano F, Sandmaier BM, Khan I, Davis C, Basom RS, Appelbaum FR, Walter RB. Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia. PMID 38388647 DOI: 10.1038/s41375-024-02172-3 |
0.328 |
|
| 2024 |
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, ... ... Othus M, et al. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Leukemia. PMID 38263433 DOI: 10.1038/s41375-024-02143-8 |
0.337 |
|
| 2023 |
Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, et al. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. PMID 37935977 DOI: 10.1038/s41375-023-02073-x |
0.378 |
|
| 2023 |
Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH, Schmidt E, Valentine Iii CC, Salk JJ, Wood BL, Erba HP, Radich JP, Hourigan CS. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. Haematologica. PMID 37534515 DOI: 10.3324/haematol.2023.283520 |
0.311 |
|
| 2023 |
Halpern AB, Rodríguez-Arbolí E, Othus M, Garcia KA, Percival MM, Cassaday RD, Oehler VG, Becker PS, Appelbaum J, Abkowitz JL, Orozco JJ, Keel SB, Hendrie P, Scott BL, Ghiuzeli CMM, et al. Phase 1/2 Study of Sorafenib Added to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone in Untreated AML. Blood Advances. PMID 37339483 DOI: 10.1182/bloodadvances.2023010392 |
0.376 |
|
| 2023 |
Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH, Schmidt E, Valentine CC, Salk JJ, Wood BL, Erba HP, Radich JP, Hourigan CS. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. Medrxiv : the Preprint Server For Health Sciences. PMID 37034683 DOI: 10.1101/2023.03.26.23287367 |
0.37 |
|
| 2023 |
Zhang MY, Othus M, Shaw C, Schonhoff KG, Halpern AB, Appelbaum J, Hendrie PC, Walter RB, Estey EH, Percival MM. Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents. Leukemia & Lymphoma. 1-7. PMID 36891630 DOI: 10.1080/10428194.2023.2186732 |
0.416 |
|
| 2023 |
Orvain C, Rodríguez-Arbolí E, Othus M, Sandmaier BM, Deeg HJ, Appelbaum FR, Walter RB. Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia. Cancers. 15. PMID 36672303 DOI: 10.3390/cancers15020352 |
0.401 |
|
| 2022 |
Walter RB, Sandmaier BM, Othus M, Orvain C, Rodríguez-Arbolí E, Oshima MU, Schoch G, Davis C, Joachim Deeg H, Storb R. Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission. Bone Marrow Transplantation. PMID 36577856 DOI: 10.1038/s41409-022-01909-x |
0.355 |
|
| 2022 |
Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, Schroeder MA, Uy GL, Law LY, Cheema F, Sweet KL, Asch AS, Liu JJ, Moseley AB, Maher T, et al. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & Lymphoma. 1-5. PMID 36517990 DOI: 10.1080/10428194.2022.2148212 |
0.306 |
|
| 2022 |
Paras G, Othus M, Schonhoff K, Shaw C, Sorror M, Halpern AB, Appelbaum J, Hendrie P, Walter RB, Estey EH, Percival MM. Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia. PMID 36434064 DOI: 10.1038/s41375-022-01745-4 |
0.307 |
|
| 2022 |
Advani AS, Moseley A, O'Dwyer KM, Wood BL, Park JH, Wieduwilt MJ, Jeyakumar D, Yaghmour G, Atallah E, Gerds AT, O'Brien SM, Liesveld JL, Othus M, Litzow MR, Stone RM, et al. Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib in Ph+ Acute Lymphoblastic Leukemia. Blood Advances. PMID 36322825 DOI: 10.1182/bloodadvances.2022008216 |
0.372 |
|
| 2022 |
Orvain C, Wilson JA, Fang M, Sandmaier BM, Rodríguez-Arbolí E, Wood BL, Othus M, Appelbaum FR, Walter RB. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Haematologica. PMID 35924583 DOI: 10.3324/haematol.2022.281585 |
0.335 |
|
| 2022 |
Othus M, Garcia-Manero G, Godwin JE, Weick JK, Appelbaum FR, Erba HP, Estey EH. Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. Haematologica. PMID 35833298 DOI: 10.3324/haematol.2022.280765 |
0.317 |
|
| 2022 |
Godwin CD, Rodríguez-Arbolí E, Othus M, Halpern AB, Appelbaum JS, Percival MM, Hendrie PC, Oehler VG, Keel SB, Abkowitz JL, Cooper JP, Cassaday RD, Estey EH, Walter RB. Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms. Cancers. 14. PMID 35740603 DOI: 10.3390/cancers14122934 |
0.33 |
|
| 2022 |
Halpern AB, Othus M, Alcorn G, Ali Z, Garcia KA, Percival MM, Keel SB, Cassaday RD, Becker PS, Estey EH, Walter RB. Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm. Leukemia. PMID 35173273 DOI: 10.1038/s41375-022-01524-1 |
0.311 |
|
| 2022 |
Advani AS, Moseley A, O'Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic RB, Baer MR, Stock W, Bhave RR, Othus M, Harvey RC, Willman CL, et al. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101766. PMID 35157496 DOI: 10.1200/JCO.21.01766 |
0.329 |
|
| 2022 |
Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, Palmieri R, Schoch G, Davis C, Bleakley M, Flowers ME, Deeg HJ, Appelbaum FR, Storb RF, Walter RB. Conditioning Intensity and Peri-Transplant Flow Cytometric MRD Dynamics in Adult AML. Blood. PMID 34995355 DOI: 10.1182/blood.2021014804 |
0.348 |
|
| 2021 |
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, et al. Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma. Cancer Discovery. PMID 34764195 DOI: 10.1158/2159-8290.CD-21-1141 |
0.344 |
|
| 2021 |
Halpern AB, Othus M, Howard NP, Hendrie PC, Percival MM, Hartley GA, Welch VL, Estey EH, Walter RB. Comparative analysis of infectious complications with outpatient inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. Leukemia & Lymphoma. 1-10. PMID 34608844 DOI: 10.1080/10428194.2021.1984451 |
0.308 |
|
| 2021 |
Othus M, Garcia-Manero G, Godwin J, Weick J, Stirewalt D, Appelbaum F, Erba H, Estey E. Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia. Leukemia & Lymphoma. 1-6. PMID 33719833 DOI: 10.1080/10428194.2021.1885663 |
0.355 |
|
| 2020 |
Palmieri R, Othus M, Halpern AB, Percival MM, Godwin CD, Becker PS, Walter RB. Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001392. PMID 33030979 DOI: 10.1200/JCO.20.01392 |
0.305 |
|
| 2020 |
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, et al. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature Medicine. PMID 33020646 DOI: 10.1038/s41591-020-1060-8 |
0.359 |
|
| 2020 |
Halpern AB, Othus M, Howard NP, Hendrie PC, Percival MM, Scott BL, Gernsheimer TB, Baclig NV, Buckley SA, Cassaday RD, Hartley GA, Welch VL, Estey EH, Walter RB. Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia & Lymphoma. 1-5. PMID 32921204 DOI: 10.1080/10428194.2020.1821008 |
0.399 |
|
| 2020 |
Othus M, Bansal A, Erba H, Ramsey S. Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 23: 1034-1039. PMID 32828215 DOI: 10.1016/J.Jval.2020.02.015 |
0.34 |
|
| 2020 |
Morsink LM, Sandmaier BM, Othus M, Palmieri R, Granot N, Bezerra ED, Wood BL, Mielcarek M, Schoch G, Davis C, Flowers MED, Deeg HJ, Appelbaum FR, Storb R, Walter RB. Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers. 12. PMID 32825022 DOI: 10.3390/Cancers12092339 |
0.442 |
|
| 2020 |
Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Jenkins IC, Fang M, Huynh M, Kopecky KJ, List AF, Naru J, Radich JP, et al. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. Biomarker Research. 8: 29. PMID 32817791 DOI: 10.1186/S40364-020-00208-1 |
0.38 |
|
| 2020 |
Sorror ML, Agarwal S, Othus M, Lynch Y, Nyland JE, Percival ME, Becker PS, Appelbaum FR, Estey EH. Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML. Cancer Medicine. PMID 32706528 DOI: 10.1002/Cam4.3311 |
0.389 |
|
| 2020 |
Percival MM, Othus M, Mirahsani S, Gardner KM, Shaw C, Halpern AB, Becker PS, Hendrie PC, Sorror ML, Walter RB, Estey EH. Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. Haematologica. PMID 32646891 DOI: 10.3324/Haematol.2020.254938 |
0.485 |
|
| 2020 |
Epperla N, Vaughn JL, Othus M, Hallack A, Costa LJ. Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab? Cancer Medicine. 9: 5519-5525. PMID 32558356 DOI: 10.1002/Cam4.3237 |
0.386 |
|
| 2020 |
Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, Litzow MR, Komrokji RS, Erba HP, Appelbaum FR. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Advances. 4: 1683-1689. PMID 32330241 DOI: 10.1182/Bloodadvances.2019001278 |
0.48 |
|
| 2020 |
Michelson AP, McDonough S, Willman CL, Koegle ER, Godwin JE, Petersdorf SH, List AF, Othus M, Appelbaum FR, Radich JP, Ganapathi MK, Advani AS, Ganapathi RN. Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia. Scientific Reports. 10: 5486. PMID 32218491 DOI: 10.1038/S41598-020-62345-9 |
0.382 |
|
| 2020 |
Palmieri R, Buckley SA, Othus M, Halpern AB, Percival MM, Scott BL, Hendrie PC, Becker PS, Oehler VG, Estey EH, Walter RB. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. Leukemia & Lymphoma. 1-4. PMID 32077361 DOI: 10.1080/10428194.2020.1728754 |
0.397 |
|
| 2020 |
Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, et al. Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. Jco Oncology Practice. JOP1900133. PMID 32048933 DOI: 10.1200/JOP.19.00133 |
0.392 |
|
| 2020 |
Morsink LM, Othus M, Bezerra ED, Wood BL, Fang M, Sandmaier BM, Mielcarek M, Schoch G, Storb R, Deeg HJ, Appelbaum FR, Walter RB. Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. Leukemia. PMID 31974434 DOI: 10.1038/S41375-020-0717-0 |
0.512 |
|
| 2020 |
Estey E, Karp JE, Emadi A, Othus M, Gale RP. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. PMID 31915366 DOI: 10.1038/S41375-019-0704-5 |
0.427 |
|
| 2020 |
Buckley SA, Halpern AB, Othus M, Jimenez-Sahagun D, Walter RB, Lee SJ. Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. Leukemia & Lymphoma. 1-10. PMID 31909637 DOI: 10.1080/10428194.2019.1709838 |
0.354 |
|
| 2020 |
Othus M, Li Y. A Gaussian Copula Model for Multivariate Survival Data. Statistics in Biosciences. 2: 154-179. PMID 22162742 DOI: 10.1007/S12561-010-9026-X |
0.36 |
|
| 2020 |
Patel SP, Othus M, Moon J, Tetzlaff MT, Buchbinder EI, Sondak VK, Lowe MC, Campos D, Sharon E, Korde LA, Carson WE, Ribas A, Grossmann KF. S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma. Journal of Clinical Oncology. 38: TPS10090-TPS10090. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps10090 |
0.442 |
|
| 2020 |
Szamreta EA, Monberg MJ, Desai K, Chen X, Othus M. Real-world conditional survival analysis of women with newly diagnosed ovarian cancer. Journal of Clinical Oncology. 38: e18087-e18087. DOI: 10.1200/Jco.2020.38.15_Suppl.E18087 |
0.395 |
|
| 2020 |
Shih L, Othus M, Gardner K, Shaw C, Halpern AB, Becker PS, Walter RB, Estey E, Percival MM. Relation between measurable residual disease and morphologic relapse in AML. Journal of Clinical Oncology. 38: 7535-7535. DOI: 10.1200/Jco.2020.38.15_Suppl.7535 |
0.525 |
|
| 2020 |
Adams S, Othus M, Patel SP, Chae YK, Miller K, Chugh R, Schuetze S, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Kurzrock R. Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36). Journal of Clinical Oncology. 38: 1073-1073. DOI: 10.1200/Jco.2020.38.15_Suppl.1073 |
0.419 |
|
| 2020 |
Algazi AP, Othus M, Voorhies BN, Kendra KL, Dakhil SR, Harker-Murray AK, Lao CD, Chmielowski B, Lo R, Grossmann KF, Ribas A. Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib. Journal of Clinical Oncology. 38: 10059-10059. DOI: 10.1200/Jco.2020.38.15_Suppl.10059 |
0.412 |
|
| 2020 |
Algazi AP, Othus M, Daud A, Mehnert JM, Truong T, Conry RM, Kendra KL, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao CD, Faller BA, Govindarajan R, Harker-Murray AK, et al. Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320. Journal of Clinical Oncology. 38: 10039-10039. DOI: 10.1200/Jco.2020.38.15_Suppl.10039 |
0.466 |
|
| 2020 |
Algazi A, Othus M, Daud A, Lo R, Mehnert J, Truong T, Conry R, Kendra K, Doolittle G, Clark JI, Messino M, Moore DF, Lao C, Faller BA, Govindarajan R, et al. Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct013 |
0.468 |
|
| 2020 |
Chae YK, Othus M, Patel SP, Zalupski M, Kasi A, Khalil M, Kalyan A, Polite B, Fenton S, Gurung S, McLeod CM, Giles F, Chen HX, Sharon E, Mayerson E, et al. Abstract 3417: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort Cancer Research. 80: 3417-3417. DOI: 10.1158/1538-7445.Am2020-3417 |
0.388 |
|
| 2019 |
Morsink LM, Bezerra ED, Othus M, Wood BL, Fang M, Sandmaier BM, Mielcarek MB, Deeg HJ, Schoch G, Appelbaum FR, Walter RB. Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia. PMID 31796913 DOI: 10.1038/S41375-019-0671-X |
0.321 |
|
| 2019 |
Hoffmann AP, Besch AL, Othus M, Morsink LM, Wood BL, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation. PMID 31685932 DOI: 10.1038/S41409-019-0739-2 |
0.365 |
|
| 2019 |
Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplantation. 55: 843-850. PMID 31666655 DOI: 10.1038/S41409-019-0729-4 |
0.363 |
|
| 2019 |
Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel SB, Orozco JJ, Cassaday RD, Shustov AR, et al. Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. Leukemia. PMID 31586148 DOI: 10.1038/S41375-019-0586-6 |
0.361 |
|
| 2019 |
Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. PMID 31073153 DOI: 10.1038/S41375-019-0477-X |
0.504 |
|
| 2019 |
Buckley SA, Mark NM, Othus M, Estey EH, Patel K, Walter RB. Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia & Lymphoma. 1-4. PMID 30856024 DOI: 10.1080/10428194.2019.1581933 |
0.356 |
|
| 2019 |
Godwin CD, Fromm JR, Othus M, Sandmaier BM, Mielcarek MB, Wood BL, Appelbaum FR, Storb R, Walter RB. Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. Bone Marrow Transplantation. PMID 30804488 DOI: 10.1038/S41409-019-0481-9 |
0.322 |
|
| 2019 |
Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, Litzow MR, Erba HP. The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). Leukemia Research. 78: 29-33. PMID 30673620 DOI: 10.1016/J.Leukres.2019.01.007 |
0.38 |
|
| 2019 |
Othus M, Li Y, Tiwari RC. A Class of Semiparametric Mixture Cure Survival Models with Dependent Censoring. Journal of the American Statistical Association. 104: 1241-1250. PMID 20706564 DOI: 10.1198/Jasa.2009.Tm08033 |
0.382 |
|
| 2019 |
Patel SP, Othus M, Chae YK, Giles F, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. Journal of Clinical Oncology. 37: TPS2658-TPS2658. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps2658 |
0.457 |
|
| 2019 |
Hochman MJ, Othus M, Shaw C, Gardner K, Percival MM, Hendrie PC, Estey E. Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)? Journal of Clinical Oncology. 37: 7031-7031. DOI: 10.1200/Jco.2019.37.15_Suppl.7031 |
0.48 |
|
| 2019 |
Gardner K, Othus M, Shaw CM, Becker PS, Halpern AB, Hendrie PC, Scott BL, Walter RB, Estey EH, Percival MM. Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS Blood. 134: 5093-5093. DOI: 10.1182/Blood-2019-130965 |
0.465 |
|
| 2019 |
Percival MM, Othus M, Mirahsani S, Gardner KM, Shaw CM, Halpern AB, Hendrie PC, Becker PS, Sorror ML, Walter RB, Estey EH. Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Blood. 134: 3824-3824. DOI: 10.1182/Blood-2019-130834 |
0.487 |
|
| 2019 |
Othus M, Garcia-Manero G, Godwin JE, Weick JK, Appelbaum FR, Erba HP, Estey EH. Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data Blood. 134: 291-291. DOI: 10.1182/Blood-2019-127356 |
0.47 |
|
| 2019 |
Godwin CD, Zhou Y, Othus M, Shaw CM, Gardner KM, Wood BL, Walter RB, Estey EH. Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow Blood. 134: 2729-2729. DOI: 10.1182/Blood-2019-127128 |
0.357 |
|
| 2019 |
Bezerra ED, Morsink LM, Othus M, Wood BL, Fang M, Sandmaier BM, Mielcarek ML, Deeg HJ, Schoch HG, Appelbaum FR, Walter RB. Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease Blood. 134: 321-321. DOI: 10.1182/blood-2019-126364 |
0.372 |
|
| 2019 |
Godwin CD, Othus M, Percival MM, Scott BL, Becker PS, Gardner KM, Keel SB, Dhawale TM, Oehler VG, Abkowitz JL, Halpern AB, Hendrie PC, Orlowski KF, Woo A, Estey EH, et al. Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm Blood. 134: 3892-3892. DOI: 10.1182/Blood-2019-126009 |
0.486 |
|
| 2019 |
Advani AS, Moseley A, Liedtke M, O'Donnell MR, Aldoss I, Mims MP, O'Dwyer KM, Othus M, Erba HP. SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia Blood. 134: 227-227. DOI: 10.1182/Blood-2019-125340 |
0.407 |
|
| 2019 |
Chen X, Othus M, Wood BL, Walter RB, Becker PS, Percival MM, Abkowitz JL, Appelbaum FR, Estey EH. Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count Blood. 134: 2692-2692. DOI: 10.1182/Blood-2019-124977 |
0.359 |
|
| 2019 |
Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel SB, Orozco J, Cassaday RD, Shustov AR, et al. Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms Blood. 134: 1317-1317. DOI: 10.1182/Blood-2019-124586 |
0.448 |
|
| 2019 |
Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Jenkins IC, Fang M, Huynh M, Kopecky KJ, List AF, Naru J, Radich JP, et al. Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report Blood. 134: 2691-2691. DOI: 10.1182/Blood-2019-124529 |
0.43 |
|
| 2019 |
Hay AE, Assouline S, Walter RB, Little RF, Moseley A, Gail SM, Im A, Foran JM, Radich JP, Fang M, Othus M, Erba HP, Michaelis LC. Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial Blood. 134: 3905-3905. DOI: 10.1182/Blood-2019-124320 |
0.392 |
|
| 2019 |
Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel S, Orozco J, Cassaday RD, Shustov AR, et al. Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms Blood. 134: 1323-1323. DOI: 10.1182/Blood-2019-123605 |
0.402 |
|
| 2019 |
Halpern AB, Othus M, Gardner K, Alcorn G, Percival MM, Huebner EM, Scott BL, Becker PS, Hendrie PC, Oehler VG, Estey EH, Walter RB. Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms Blood. 134: 1364-1364. DOI: 10.1182/Blood-2019-123542 |
0.48 |
|
| 2019 |
Kopmar NE, Othus M, Gardner K, Shaw CM, Halpern AB, Scott BL, Hendrie PC, Walter RB, Becker PS, Estey EH, Percival MM. Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting Blood. 134: 2214-2214. DOI: 10.1182/Blood-2019-123315 |
0.519 |
|
| 2019 |
Patel SP, Othus M, Chae YK, Giles F, Hansel D, Singh P, Fontaine A, Shah M, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, MMcLeod C, et al. Abstract CT039: A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct039 |
0.411 |
|
| 2018 |
Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, et al. Phase 1/2 trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms. Haematologica. PMID 30409798 DOI: 10.3324/Haematol.2018.204792 |
0.4 |
|
| 2018 |
Othus M, Sekeres MA, Nand S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey E. Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia. 33: 371-378. PMID 30315234 DOI: 10.1038/S41375-018-0275-X |
0.476 |
|
| 2018 |
Othus M, Estey EH, Garcia-Manero G, Wood BL, Stirewalt DL, Godwin JE, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB. Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia. PMID 30315233 DOI: 10.1038/S41375-018-0274-Y |
0.431 |
|
| 2018 |
Buckley SA, Percival ME, Othus M, Halpern AB, Huebner EM, Becker PS, Shaw C, Shadman M, Walter RB, Estey EH. A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leukemia & Lymphoma. 1-7. PMID 30277112 DOI: 10.1080/10428194.2018.1516036 |
0.526 |
|
| 2018 |
Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. PMID 29720734 DOI: 10.1038/S41375-018-0135-8 |
0.451 |
|
| 2018 |
Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29684564 DOI: 10.1016/J.Bbmt.2018.04.017 |
0.41 |
|
| 2018 |
Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, Advani A, Nand S, Ravandi F, Mukherjee S, Sekeres MA. Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies. Blood. PMID 29618479 DOI: 10.1182/Blood-2018-01-826693 |
0.429 |
|
| 2018 |
Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia Research. 67: 17-20. PMID 29407182 DOI: 10.1016/J.Leukres.2018.01.021 |
0.504 |
|
| 2018 |
Ustun C, Le-Rademacher J, Wang H, Othus M, Sun Z, Major B, Zhang M, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Bloomfield CD, Cripe LD, Larson RA, et al. Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study Blood. 132: 2170-2170. DOI: 10.1182/Blood-2018-99-118383 |
0.436 |
|
| 2018 |
Othus M, Garcia-Manero G, Appelbaum FR, Erba HP, Walter RB. Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203 Blood. 132: 1403-1403. DOI: 10.1182/Blood-2018-99-117565 |
0.417 |
|
| 2018 |
Othus M, Estey EH, Garcia-Manero G, Wood B, Stirewalt D, Godwin J, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB. 2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials Blood. 132: 3978-3978. DOI: 10.1182/Blood-2018-99-117525 |
0.497 |
|
| 2018 |
Yin J, Uy GL, Laplant B, Storrick E, Marcucci G, Fernandez HF, Sun Z, Litzow MR, Othus M, Appelbaum FR, Larson RA, Stone RM, Mandrekar SJ. Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614) Blood. 132: 1386-1386. DOI: 10.1182/Blood-2018-99-113902 |
0.496 |
|
| 2018 |
Advani AS, Moseley A, O'Dwyer KM, Wood B, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic R, Baer MR, Stock W, Bhave R, Othus M, Litzow MR, Stone RM, et al. Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia Blood. 132: 33-33. DOI: 10.1182/Blood-2018-99-111992 |
0.384 |
|
| 2018 |
Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee SJ. Validation of the AML-QOL: A Quality of Life Instrument for Patients with Acute Myeloid Leukemia and Other Aggressive Myeloid Neoplasms Blood. 132: 4822-4822. DOI: 10.1182/Blood-2018-99-110410 |
0.371 |
|
| 2018 |
Ramsey S, Othus M, Roth J, Yuan Y, Wagner S, Penrod J. PRM126 - A COMPARISON OF MIXTURE CURE AND STANDARD PARAMETRIC MODELING TO ESTIMATE LONG-TERM SURVIVAL FOR SMALL-CELL LUNG CANCER IN PATIENTS TREATED WITH NIVOLUMAB AFTER PROGRESSION Value in Health. 21: S377. DOI: 10.1016/J.Jval.2018.09.2246 |
0.333 |
|
| 2017 |
Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH. Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. PMID 29242304 DOI: 10.3324/Haematol.2017.182642 |
0.409 |
|
| 2017 |
Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Pogosov GL, Radich JP, Willman CL, Wood BL, et al. Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. Biopreservation and Biobanking. PMID 29172682 DOI: 10.1089/Bio.2017.0079 |
0.408 |
|
| 2017 |
Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, et al. Intergroup LEAP Trial (S1612): A Randomized Phase 2/3 Platform Trial to Test Novel Therapeutics in Medically Less Fit Older Adults with Acute Myeloid Leukemia. American Journal of Hematology. PMID 29164656 DOI: 10.1002/Ajh.24980 |
0.336 |
|
| 2017 |
Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Medicine. PMID 28994212 DOI: 10.1002/Cam4.1223 |
0.459 |
|
| 2017 |
Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee SJ. Quality of life from the perspective of the patient with acute myeloid leukemia. Cancer. PMID 28881384 DOI: 10.1002/Cncr.30982 |
0.337 |
|
| 2017 |
Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival ME, Estey EH, Stirewalt DL, Walter RB. Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study. Leukemia. PMID 28555084 DOI: 10.1038/Leu.2017.165 |
0.492 |
|
| 2017 |
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, et al. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2015662510. PMID 28486043 DOI: 10.1200/Jco.2015.66.2510 |
0.491 |
|
| 2017 |
Korn EL, Othus M, Chen T, Freidlin B. Assessing treatment efficacy in the subset of responders in a randomized clinical trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28444115 DOI: 10.1093/Annonc/Mdx197 |
0.32 |
|
| 2017 |
Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for Cured Patients in Cost-Effectiveness Analysis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 20: 705-709. PMID 28408015 DOI: 10.1016/J.Jval.2016.04.011 |
0.425 |
|
| 2017 |
Chen X, Othus M, Wood BL, Walter RB, Percival MM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH. Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia. Leukemia & Lymphoma. 1-3. PMID 28351184 DOI: 10.1080/10428194.2017.1307359 |
0.309 |
|
| 2017 |
Qu X, Othus M, Davison J, Wu Y, Yan L, Meshinchi S, Ostronoff F, Estey EH, Radich JP, Erba HP, Appelbaum FR, Fang M. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. Cancer. PMID 28222251 DOI: 10.1002/Cncr.30626 |
0.403 |
|
| 2017 |
Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. PMID 28126965 DOI: 10.3324/Haematol.2016.159343 |
0.435 |
|
| 2017 |
Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, ... ... Othus M, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. PMID 28082441 DOI: 10.1182/Blood-2016-10-747170 |
0.432 |
|
| 2017 |
Torra OS, Othus M, Williamson DW, Wood B, Kirsch I, Robins H, Beppu L, O'Donnell MR, Forman SJ, Appelbaum FR, Radich JP. Next Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28062215 DOI: 10.1016/J.Bbmt.2016.12.639 |
0.375 |
|
| 2017 |
Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee S. Determinants of quality of life in patients with acute myeloid leukemia. Journal of Clinical Oncology. 35: e18528-e18528. DOI: 10.1200/Jco.2017.35.15_Suppl.E18528 |
0.341 |
|
| 2017 |
Algazi AP, Moon J, Chmielowski B, Lo R, Kendra KL, Lao CD, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Othus M, Ribas A. SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173). Journal of Clinical Oncology. 35: 2578-2578. DOI: 10.1200/Jco.2017.35.15_Suppl.2578 |
0.332 |
|
| 2017 |
Halpern AB, Huebner EM, Othus M, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Buckley SA, Estey EH, Walter RB. G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial Blood. 130: 149-149. DOI: 10.1182/Blood.V130.Suppl_1.149.149 |
0.514 |
|
| 2017 |
Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH. Randomized Study of CPX-351 for Medically Less-Fit Adults with Newly Diagnosed Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm Blood. 130: 1346-1346. DOI: 10.1182/Blood.V130.Suppl_1.1346.1346 |
0.356 |
|
| 2017 |
Othus M, Garcia-Manero G, Godwin J, Weick JK, Anderson JE, Stirewalt D, Appelbaum FR, Erba HP, Estey EH. Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data Blood. 130: 1301-1301. DOI: 10.1182/Blood.V130.Suppl_1.1301.1301 |
0.419 |
|
| 2016 |
Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, et al. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Advances. 1: 250-259. PMID 29046900 DOI: 10.1182/Bloodadvances.2016001495 |
0.478 |
|
| 2016 |
Delaney C, Milano F, Cicconi L, Othus M, Becker PS, Sandhu V, Nicoud I, Dahlberg A, Bernstein ID, Appelbaum FR, Estey EH. Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. The Lancet. Haematology. 3: e330-9. PMID 27374466 DOI: 10.1016/S2352-3026(16)30023-0 |
0.363 |
|
| 2016 |
Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP, Walter RB. Effect of measurable ("minimal") residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia. PMID 27133827 DOI: 10.1038/Leu.2016.120 |
0.381 |
|
| 2016 |
Othus M, Mukherjee S, Sekeres MA, Godwin J, Petersdorf S, Appelbaum FR, Erba H, Estey E. Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia. PMID 27055872 DOI: 10.1038/Leu.2016.48 |
0.392 |
|
| 2016 |
Othus M, van Putten W, Lowenberg B, Petersdorf SH, Nand S, Erba H, Appelbaum F, Hills R, Russell N, Burnett A, Estey E. Relationhip between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVN/SAKK, and MRC/NCRI. Haematologica. PMID 27013652 DOI: 10.3324/Haematol.2015.138552 |
0.373 |
|
| 2016 |
Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. PMID 27012865 DOI: 10.1038/Leu.2016.46 |
0.45 |
|
| 2016 |
Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin JE, Appelbaum FR, Radich JP, Erba HP, Nand S, Zeleznik-Le NJ. Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leukemia Research. PMID 26818573 DOI: 10.1016/J.Leukres.2016.01.004 |
0.388 |
|
| 2016 |
Godwin CD, Othus M, Powell MA, Buckley SA, Estey EH, Walter RB. Prediction of early death in adults with relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma. 1-4. PMID 26754357 DOI: 10.3109/10428194.2015.1135436 |
0.346 |
|
| 2016 |
Grossmann KF, Othus M, Tarhini AA, Patel SP, Moon J, Sondak VK, Kirkwood JM, Ribas A. SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma. Journal of Clinical Oncology. 34: e21032-e21032. DOI: 10.1200/Jco.2016.34.15_Suppl.E21032 |
0.444 |
|
| 2016 |
Garcia-Manero G, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow M, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, et al. SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) Blood. 128: 901-901. DOI: 10.1182/Blood.V128.22.901.901 |
0.379 |
|
| 2016 |
Lancet JE, Moseley A, Komrokji RS, Coutre SE, DeAngelo DJ, Tallman MS, Litzow M, Othus M, Appelbaum FR. ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial Blood. 128: 896-896. DOI: 10.1182/Blood.V128.22.896.896 |
0.499 |
|
| 2016 |
Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre SE, Advani AS, Nand S, Ravandi F, Mukherjee S, Sekeres MA. Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies Blood. 128: 4002-4002. DOI: 10.1182/Blood.V128.22.4002.4002 |
0.483 |
|
| 2016 |
Pogosova-Agadjanyan EL, Moseley A, Wood BL, Appelbaum FR, Chauncey T, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Othus M, Radich JP, Willman CL, Meshinchi S, et al. Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report Blood. 128: 2890-2890. DOI: 10.1182/Blood.V128.22.2890.2890 |
0.385 |
|
| 2016 |
Selim D, Alonzo TA, Othus M, Gerbing R, Ostronoff F, Tarlock K, Kutny MA, Aplenc R, Kolb EA, Radich JP, Appelbaum FR, Gamis AS, Stirewalt DL, Meshinchi S. Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration Blood. 128: 285-285. DOI: 10.1182/Blood.V128.22.285.285 |
0.402 |
|
| 2016 |
Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Kanakry CG, Gruhn B, Devine B, Walter RB. The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis Blood. 128: 2842-2842. DOI: 10.1182/Blood.V128.22.2842.2842 |
0.45 |
|
| 2016 |
Advani AS, Moseley A, Liedtke M, O'Donnell M, Othus M, Mims MP, O'Dwyer K, Erba HP. A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia (SWOG 1312) Blood. 128: 1634-1634. DOI: 10.1182/Blood.V128.22.1634.1634 |
0.382 |
|
| 2016 |
Othus M, Sekeres MA, Nand S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey EH. Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival Blood. 128: 1613-1613. DOI: 10.1182/Blood.V128.22.1613.1613 |
0.432 |
|
| 2016 |
Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow M, Savoie ML, Spellman SR, Confer DL, Chell J, Brown M, Medeiros BC, et al. Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat Blood. 128: 1166-1166. DOI: 10.1182/Blood.V128.22.1166.1166 |
0.445 |
|
| 2016 |
Halpern AB, Othus M, Huebner EM, Orlowski KF, Scott BL, Smith HA, Becker PS, Percival MM, Hendrie PC, Perdue AM, Chen TL, Buckley SA, Erba HP, Estey EH, Walter RB. A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Blood. 128: 1068-1068. DOI: 10.1182/Blood.V128.22.1068.1068 |
0.485 |
|
| 2016 |
Grossmann KF, Sondak VK, Othus M, Tarhini A, Patel S, Kirkwood JM, Ribas A, Moon J. Abstract CT125: A phase III randomized trial comparing FDA approved standard of care adjuvant therapy to one year of pembrolizumab in patients with high risk resected melanoma. SWOG 1404 Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct125 |
0.427 |
|
| 2016 |
Buckley SA, Percival MM, Othus M, Halpern AB, Huebner EM, Shaw C, Hendrie PC, Shadman M, Becker PS, Walter RB, Estey EH. A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study Blood. 128: 2787-2787. DOI: 10.1016/J.Clml.2017.07.062 |
0.534 |
|
| 2015 |
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26668349 DOI: 10.1182/Blood.V126.23.2571.2571 |
0.437 |
|
| 2015 |
Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis. Jama Oncology. 1-8. PMID 26355382 DOI: 10.1001/Jamaoncol.2015.2969 |
0.392 |
|
| 2015 |
Walter RB, Othus M, Löwenberg B, Ossenkoppele GJ, Petersdorf SH, Pabst T, Vekemans MC, Appelbaum FR, Erba HP, Estey EH. Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. Haematologica. 100: e409-11. PMID 26160876 DOI: 10.3324/Haematol.2015.130013 |
0.462 |
|
| 2015 |
Araki D, Othus M, Walter RB, Sandhu V, Sandmaier BM, Becker PS, Appelbaum FR, Estey EH. Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. Haematologica. 100: e254-6. PMID 25795719 DOI: 10.3324/Haematol.2014.118570 |
0.429 |
|
| 2015 |
Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW, Sun Z, Tallman MS, Patel J, Gönen M, Abdel-Wahab O, Levine RL, Estey EH. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. PMID 25772026 DOI: 10.1038/Leu.2015.76 |
0.352 |
|
| 2015 |
Bar M, Othus M, Park HM, Sandhu V, Chen X, Wood BL, Estey E. Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission. Leukemia & Lymphoma. 1-7. PMID 25726954 DOI: 10.3109/10428194.2015.1020060 |
0.389 |
|
| 2015 |
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, et al. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1157-64. PMID 25713434 DOI: 10.1200/Jco.2014.58.0571 |
0.475 |
|
| 2015 |
Buckley SA, Othus M, Estey EH, Walter RB. The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy Blood Cancer Journal. 5: e276. PMID 25635529 DOI: 10.1038/Bcj.2014.97 |
0.344 |
|
| 2015 |
Bar M, Tong W, Othus M, Loeb KR, Estey EH. Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 546-51. PMID 25545726 DOI: 10.1016/J.Bbmt.2014.11.683 |
0.435 |
|
| 2015 |
Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. American Journal of Hematology. 90: 295-300. PMID 25545153 DOI: 10.1002/Ajh.23927 |
0.465 |
|
| 2015 |
Othus M, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Nevill T, Brandwein J, Larson RA, Stiff PJ, Walter RB, Tallman MS, Stenke L, Erba HP. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 559-64. PMID 25536215 DOI: 10.1016/J.Bbmt.2014.10.025 |
0.495 |
|
| 2015 |
Medeiros BC, Othus M, Fang M, Appelbaum FR, Erba HP. Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. Haematologica. 100: 331-5. PMID 25527568 DOI: 10.3324/Haematol.2014.117267 |
0.497 |
|
| 2015 |
Araki D, Othus M, Walter RB, Becker PS, Sandhu V, Estey EH. Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy? Leukemia and Lymphoma. 1-3. DOI: 10.3109/10428194.2015.1079316 |
0.342 |
|
| 2015 |
Algazi AP, Othus M, Daud A, Mehnert JM, Lao CD, Kudchadkar RR, Grossmann KF, Lo R, Moon J, Kirkwood JM, Ribas A. SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma. Journal of Clinical Oncology. 33: TPS9093-TPS9093. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps9093 |
0.374 |
|
| 2015 |
Grossmann KF, Othus M, Tarhini AA, Patel SP, Kirkwood JM, Moon J, Sondak VK, Ribas A. SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma. Journal of Clinical Oncology. 33: TPS9085-TPS9085. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps9085 |
0.428 |
|
| 2015 |
Tong W, Othus M, Sandhu V, Chen X, Becker PS, Pagel J, Walter RB, Wood BL, Estey E. Discrepancy in bone marrow blast counts between morphology and flow cytometry and its potential clinical implications. Journal of Clinical Oncology. 33: e18031-e18031. DOI: 10.1200/Jco.2015.33.15_Suppl.E18031 |
0.364 |
|
| 2015 |
Nand S, Achille N, Othus M, Phelan KW, Zhang S, Cooper KA, Godwin JE, Appelbaum FR, Radich JP, Erba HP, Zeleznik-Le N. Association between early promoter methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT0065884). Journal of Clinical Oncology. 33: 7060-7060. DOI: 10.1200/Jco.2015.33.15_Suppl.7060 |
0.437 |
|
| 2015 |
Lancet JE, Othus M, DeAngelo DJ, Coutre S, Komrokji RS, Tallman MS, Litzow MR, Appelbaum FR. Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial. Journal of Clinical Oncology. 33: 7016-7016. DOI: 10.1200/Jco.2015.33.15_Suppl.7016 |
0.411 |
|
| 2015 |
Ravandi F, Othus M, O'Brien S, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, et al. Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60 Blood. 126: 796-796. DOI: 10.1182/Blood.V126.23.796.796 |
0.496 |
|
| 2015 |
Qu X, Othus M, Davison J, Yan L, Estey EH, Radich J, Erba HP, Appelbaum FR, Fang M. Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials Blood. 126: 688-688. DOI: 10.1182/Blood.V126.23.688.688 |
0.442 |
|
| 2015 |
Buckley SA, Othus M, Hendrie PC, Estey EH, Walter RB. Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study Blood. 126: 5635-5635. DOI: 10.1182/Blood.V126.23.5635.5635 |
0.407 |
|
| 2015 |
Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR. Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia Blood. 126: 3803-3803. DOI: 10.1182/blood.V126.23.3803.3803 |
0.369 |
|
| 2015 |
Ostronoff F, Alonzo TA, Othus M, Kutny MA, Gerbing RB, Radich JP, Erba HP, Appelbaum FR, Kolb EA, Gamis AS, Stirewalt DL, Meshinchi S. Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106 Blood. 126: 2576-2576. DOI: 10.1182/Blood.V126.23.2576.2576 |
0.385 |
|
| 2015 |
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? Blood. 126: 2571-2571. DOI: 10.1182/blood.v126.23.2571.2571 |
0.4 |
|
| 2015 |
Othus M, Wood BL, Estey EH, Petersdorf S, Appelbaum FR, Erba HP, Walter RB. Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia Blood. 126: 2569-2569. DOI: 10.1182/Blood.V126.23.2569.2569 |
0.473 |
|
| 2015 |
Zhou Y, Araki D, Othus M, Radich JP, Halpern AB, Mielcarek M, Estey EH, Wood BL, Appelbaum FR, Walter RB. Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation Blood. 126: 173-173. DOI: 10.1182/Blood.V126.23.173.173 |
0.464 |
|
| 2015 |
Anwar A, Halpern AB, Othus M, Scott BL, Hendrie PC, Becker PS, Perdue AM, Smith HA, Chen TL, Buckley SA, Orlowski KF, Powell MA, Estey EH, Walter RB. Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) Blood. 126: 1339-1339. DOI: 10.1182/Blood.V126.23.1339.1339 |
0.469 |
|
| 2015 |
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, Appelbaum FR, Estey EH. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center Leukemia. 29: 312-320. DOI: 10.1038/Leu.2014.242 |
0.412 |
|
| 2015 |
Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Cure Models: Accounting For Cured Patients In Economic Evaluations Value in Health. 18: A7. DOI: 10.1016/J.Jval.2015.03.049 |
0.308 |
|
| 2015 |
Halpern AB, Anwar A, Scott BL, Becker PS, Othus M, Hendrie PC, Ranker EM, Perdue A, Smith HA, Chen TL, Buckley SA, Orlowski KF, Powell MA, Estey EH, Walter RB. Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed AML or High-Risk MDS Clinical Lymphoma Myeloma and Leukemia. 15: S11. DOI: 10.1016/J.Clml.2015.07.027 |
0.312 |
|
| 2015 |
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. Allogeneic Hematopoietic Cell Transplantation for AML: is it Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? Clinical Lymphoma Myeloma and Leukemia. 15: S8. DOI: 10.1016/J.Clml.2015.07.020 |
0.318 |
|
| 2014 |
Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3771-8. PMID 25332243 DOI: 10.1200/Jco.2013.53.1590 |
0.371 |
|
| 2014 |
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 124: 2400-7. PMID 25145343 DOI: 10.1182/Blood-2014-04-570929 |
0.455 |
|
| 2014 |
Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. British Journal of Haematology. 167: 233-7. PMID 25039477 DOI: 10.1111/Bjh.13035 |
0.513 |
|
| 2014 |
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials The Lancet Oncology. 15: 986-996. PMID 25008258 DOI: 10.1016/S1470-2045(14)70281-5 |
0.454 |
|
| 2014 |
Carson WE, Unger JM, Sosman JA, Flaherty LE, Tuthill RJ, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A, Sondak VK. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunology Research. 2: 981-7. PMID 24994597 DOI: 10.1158/2326-6066.Cir-14-0052 |
0.374 |
|
| 2014 |
Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology. 165: 504-9. PMID 24579885 DOI: 10.1111/Bjh.12778 |
0.384 |
|
| 2014 |
Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. British Journal of Haematology. 165: 497-503. PMID 24528179 DOI: 10.1111/Bjh.12775 |
0.494 |
|
| 2014 |
Erba HP, Othus M, Walter RB, Kirschbaum MH, Tallman MS, Larson RA, Slovak ML, Kopecky KJ, Gundacker HM, Appelbaum FR. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leukemia Research. 38: 329-33. PMID 24411921 DOI: 10.1016/J.Leukres.2013.12.001 |
0.44 |
|
| 2014 |
Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. British Journal of Haematology. 164: 245-50. PMID 24383844 DOI: 10.1111/Bjh.12625 |
0.495 |
|
| 2014 |
Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH, Walter RB. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes American Journal of Hematology. 89: 423-428. PMID 24382796 DOI: 10.1002/Ajh.23661 |
0.439 |
|
| 2014 |
Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia. 28: 289-92. PMID 23760400 DOI: 10.1038/Leu.2013.176 |
0.47 |
|
| 2014 |
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Velasco Mr, Gaur R, Atallah E, Attar E, Appelbaum FR, Erba HP. A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117 Blood. 124: LBA-5-LBA-5. DOI: 10.1182/Blood.V124.21.Lba-5.Lba-5 |
0.457 |
|
| 2014 |
Walter RB, Orlowski KF, Powell MA, Becker PS, Hendrie PC, Ostronoff F, Ranker EM, Othus M, Louie AC, Estey EH. Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality Blood. 124: 994-994. DOI: 10.1182/Blood.V124.21.994.994 |
0.496 |
|
| 2014 |
Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee J, Sun Z, Tallman MS, Patel JP, Gönen M, Abdel-Wahab O, Levine RL, Estey EH. Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia Blood. 124: 941-941. DOI: 10.1182/Blood.V124.21.941.941 |
0.472 |
|
| 2014 |
Araki D, Othus M, Walter RB, Sandmaier BM, Becker PS, Sandhu V, Appelbaum FR, Estey EH. Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia Blood. 124: 5257-5257. DOI: 10.1182/Blood.V124.21.5257.5257 |
0.469 |
|
| 2014 |
Bar M, Tong W, Othus M, Loeb KR, Estey EH. Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Blood. 124: 3941-3941. DOI: 10.1182/Blood.V124.21.3941.3941 |
0.452 |
|
| 2014 |
Halpern AB, Estey EH, Othus M, Orlowski KF, Powell MA, Chen TL, Becker PS, Scott BL, Hendrie PC, Ostronoff F, Ranker EM, Shadman M, Stirewalt DL, Walter RB. Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study Blood. 124: 3730-3730. DOI: 10.1182/Blood.V124.21.3730.3730 |
0.502 |
|
| 2014 |
Walter RB, Othus M, Löwenberg B, Ossenkoppele GJ, Petersdorf SH, Pabst T, Vekemans M, Appelbaum FR, Erba HP, Estey EH. Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG Blood. 124: 3676-3676. DOI: 10.1182/Blood.V124.21.3676.3676 |
0.493 |
|
| 2014 |
Sala Torra O, Othus M, Williamson DW, Wood BL, Kirsch I, Robins H, O'Donnell M, Forman SJ, Appelbaum FR, Radich JP. Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333 Blood. 124: 2399-2399. DOI: 10.1182/Blood.V124.21.2399.2399 |
0.383 |
|
| 2014 |
Godwin C, Othus M, Sandhu V, Estey EH, Walter RB. Prediction of Treatment-Related Mortality in Patients with Relapsed and Refractory Acute Myeloid Leukemia Blood. 124: 2277-2277. DOI: 10.1182/Blood.V124.21.2277.2277 |
0.498 |
|
| 2014 |
Buckley SA, Othus M, Estey EH, Walter RB. The Treatment Related Mortality Score Predicts Early Adverse Events during Intensive Induction Chemotherapy for Acute Myeloid Leukemia (AML) Blood. 124: 2276-2276. DOI: 10.1182/Blood.V124.21.2276.2276 |
0.433 |
|
| 2013 |
Woods WG, Franklin AR, Alonzo TA, Gerbing RB, Donohue KA, Othus M, Horan J, Appelbaum FR, Estey EH, Bloomfield CD, Larson RA. Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 119: 4170-9. PMID 24104597 DOI: 10.1002/Cncr.28344 |
0.359 |
|
| 2013 |
Nand S, Othus M, Godwin JE, Willman CL, Norwood TH, Howard DS, Coutre SE, Erba HP, Appelbaum FR. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 122: 3432-9. PMID 24092933 DOI: 10.1182/Blood-2013-06-506592 |
0.488 |
|
| 2013 |
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, et al. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. British Journal of Haematology. 163: 130-2. PMID 23829510 DOI: 10.1111/Bjh.12450 |
0.343 |
|
| 2013 |
Chen TL, Estey EH, Othus M, Gardner KM, Markle LJ, Walter RB. Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study. Leukemia & Lymphoma. 54: 2534-6. PMID 23432687 DOI: 10.1182/Blood.V120.21.4343.4343 |
0.477 |
|
| 2013 |
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KGM, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients Blood. 121: 2424-2431. PMID 23325837 DOI: 10.1182/Blood-2012-10-462440 |
0.414 |
|
| 2013 |
Roshal M, Chien S, Othus M, Wood BL, Fang M, Appelbaum FR, Estey EH, Papayannopoulou T, Becker PS. The proportion of CD34+ CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia Leukemia. 27: 728-731. PMID 22926686 DOI: 10.1038/Leu.2012.217 |
0.34 |
|
| 2013 |
Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia. 27: 238-41. PMID 22722750 DOI: 10.1038/Leu.2012.168 |
0.382 |
|
| 2013 |
Advani AS, McDonough S, Copelan E, Willman CL, Mulford DA, List AF, Sekeres MA, Othus M, Erba HP, Appelbaum FR. SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML). Journal of Clinical Oncology. 31: 7028-7028. DOI: 10.1200/Jco.2013.31.15_Suppl.7028 |
0.449 |
|
| 2013 |
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center Blood. 122: 64-64. DOI: 10.1182/Blood.V122.21.64.64 |
0.516 |
|
| 2013 |
Chien S, Haq SU, Pawlus M, Moon RT, Estey EH, Appelbaum FR, Othus M, Magnani JL, Becker PS. Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation Blood. 122: 61-61. DOI: 10.1182/Blood.V122.21.61.61 |
0.364 |
|
| 2013 |
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG Blood. 122: 488-488. DOI: 10.1182/Blood.V122.21.488.488 |
0.514 |
|
| 2013 |
Othus M, Sudipto M, Sekeres MA, Godwin J, Anderson JE, Petersdorf S, Appelbaum FR, Erba HP, Estey EH. Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic Blood. 122: 3924-3924. DOI: 10.1182/Blood.V122.21.3924.3924 |
0.392 |
|
| 2013 |
Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH, Walter RB. Adverse Events During Intensive Induction Chemotherapy For Acute Myeloid Leukemia (AML) Or High-Grade Myelodysplastic Syndromes (MDS) Blood. 122: 3899-3899. DOI: 10.1182/Blood.V122.21.3899.3899 |
0.477 |
|
| 2013 |
Hills RK, Petersdorf S, Estey EH, Othus M, Appelbaum FR, Castaigne S, Dombret H, Chevret S, Delaunay J, Ifrah N, Cahn J, Recher C, Burnett AK. The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials Blood. 122: 356-356. DOI: 10.1182/Blood.V122.21.356.356 |
0.498 |
|
| 2013 |
Vaughn JE, Powell MA, Gardner KM, Othus M, Rajendra R, Rizutto D, Becker PS, Hendrie PC, Shustov AR, Keel SB, Oehler VG, Gernsheimer TB, Abkowitz JL, Estey EH, Walter RB. Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML Blood. 122: 2932-2932. DOI: 10.1182/Blood.V122.21.2932.2932 |
0.463 |
|
| 2013 |
Ravandi F, Othus M, Faderl SH, Stirewalt DL, Pierce SR, Borthakur G, Godwin J, Anderson JE, Petersdorf S, Cortes JE, Ostronoff F, Pogosova-Agadijanyan E, Appelbaum FR, Kantarjian HM, Estey EH. Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report Blood. 122: 2686-2686. DOI: 10.1182/Blood.V122.21.2686.2686 |
0.422 |
|
| 2013 |
Fang M, McDonough S, Othus M, Zhuo LT, Roulston D, Erba HP, Appelbaum FR. Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing – Retrospective Review Of The SWOG Experience Blood. 122: 1383-1383. DOI: 10.1182/Blood.V122.21.1383.1383 |
0.407 |
|
| 2013 |
Ostronoff F, Othus M, Meshinchi S, Godwin JE, Kopecky KJ, List A, Oehler VG, Petersdorf S, Pogosova-Agadjanyan EL, Radich J, Willman CL, Appelbaum FR, Stirewalt DL. Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report Blood. 122: 1315-1315. DOI: 10.1182/Blood.V122.21.1315.1315 |
0.472 |
|
| 2012 |
Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512 Plos One. 7. PMID 23226204 DOI: 10.1371/Journal.Pone.0048787 |
0.445 |
|
| 2012 |
Lin A, Othus M, McQuary A, Chi M, Estey E. Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma. 54: 541-6. PMID 22852586 DOI: 10.3109/10428194.2012.717278 |
0.393 |
|
| 2012 |
Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Douglas Smith B, Greer JM, Michelle Drye D, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, ... ... Othus M, et al. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia Haematologica. 97: 1736-1742. PMID 22733022 DOI: 10.3324/Haematol.2012.062539 |
0.411 |
|
| 2012 |
Othus M, Barlogie B, Leblanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3731-6. PMID 22675175 DOI: 10.1158/1078-0432.Ccr-11-2859 |
0.346 |
|
| 2012 |
Othus M, Li Y, Tiwari R. Change point-cure models with application to estimating the change-point effect of age of diagnosis among prostate cancer patients. Journal of Applied Statistics. 39: 901-911. PMID 22544992 DOI: 10.1080/02664763.2011.626849 |
0.326 |
|
| 2012 |
Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica. 97: 1401-4. PMID 22315487 DOI: 10.3324/Haematol.2011.056390 |
0.38 |
|
| 2012 |
Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL, Othus M, Sosman JA, Kirkwood JM, Sondak VK. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1129-37. PMID 22228638 DOI: 10.1158/1078-0432.Ccr-11-2488 |
0.442 |
|
| 2012 |
Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE. CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma. Journal of Clinical Oncology. 30: 8527-8527. DOI: 10.1200/Jco.2012.30.15_Suppl.8527 |
0.441 |
|
| 2012 |
Margolin KA, Moon J, Redman BG, Chidiac T, Othus M, Ribas A, Flaherty LE, Sondak VK, Gajewski T. Phase II trial of RO4929097 Notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933. Journal of Clinical Oncology. 30: 8525-8525. DOI: 10.1200/Jco.2012.30.15_Suppl.8525 |
0.363 |
|
| 2012 |
Nand S, Gundacker H, Godwin JE, Willman CL, Norwood T, Erba HP, Howard DS, Coutre SE, Othus M, Appelbaum FR. A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol—Report on the good-risk patients. Journal of Clinical Oncology. 30: 6502-6502. DOI: 10.1200/Jco.2012.30.15_Suppl.6502 |
0.49 |
|
| 2012 |
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SA, Appelbaum FR, Estey EH. Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center Blood. 120: 540-540. DOI: 10.1182/Blood.V120.21.540.540 |
0.476 |
|
| 2012 |
Chen TL, Estey EH, Othus M, Gardner KM, Markle L, Walter RB. Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study Blood. 120: 4343-4343. DOI: 10.1182/blood.v120.21.4343.4343 |
0.37 |
|
| 2012 |
Becker PS, Medeiros BC, Stein AS, Appelbaum FR, Scott BL, Delaney C, Othus M, Hendrie PC, Gardner KM, Petersdorf S, Pagel JM, Walter RB, Parks C, Estey EH. Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm Blood. 120: 3594-3594. DOI: 10.1182/Blood.V120.21.3594.3594 |
0.491 |
|
| 2012 |
Nand S, Othus M, Godwin JE, Willman CL, Norwood T, Erba HP, Howard D, Coutre SE, Appelbaum FR. A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients Blood. 120: 3584-3584. DOI: 10.1182/Blood.V120.21.3584.3584 |
0.495 |
|
| 2012 |
Advani A, McDonough S, Coutre S, Wood BL, Radich JP, Mims M, O'Donnell M, Elkins S, Becker MW, Othus M, Appelbaum FR. Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia. Blood. 120: 2603-2603. DOI: 10.1182/Blood.V120.21.2603.2603 |
0.371 |
|
| 2012 |
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf S, Godwin JE, Willman CL, Pierce SA, List AF, et al. A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood. 120: 2590-2590. DOI: 10.1182/Blood.V120.21.2590.2590 |
0.47 |
|
| 2012 |
Othus M, Kantarjian HM, Petersdorf S, Ravandi F, Cortes JE, Pierce SA, Erba HP, Faderl S, Appelbaum FR, Estey EH. Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA) Blood. 120: 129-129. DOI: 10.1182/Blood.V120.21.129.129 |
0.452 |
|
| 2011 |
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4417-23. PMID 21969499 DOI: 10.1200/Jco.2011.35.7525 |
0.403 |
|
| 2011 |
Medeiros BC, Othus M, Fang M, Appelbaum FR, Estey EH. Impact of residual normal metaphases in core binding factor acute myeloid leukemia. Cancer. 118: 2420-3. PMID 21928314 DOI: 10.1002/Cncr.26557 |
0.415 |
|
| 2011 |
Fang M, Storer B, Estey E, Othus M, Zhang L, Sandmaier BM, Appelbaum FR. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood. 118: 1490-4. PMID 21680797 DOI: 10.1182/Blood-2011-02-339721 |
0.483 |
|
| 2011 |
Xie B, Othus M, Medeiros BC, Fang M, Appelbaum FR, Estey EH. Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. Haematologica. 96: 631-2. PMID 21330329 DOI: 10.3324/Haematol.2010.037838 |
0.471 |
|
| 2011 |
Alexander BM, Othus M, Caglar HB, Allen AM. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy International Journal of Radiation Oncology Biology Physics. 79: 1381-1387. PMID 20605346 DOI: 10.1016/J.Ijrobp.2009.12.060 |
0.354 |
|
| 2011 |
Ostronoff F, Othus M, Ho PA, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report, Blood. 118: 3519-3519. DOI: 10.1182/Blood.V118.21.3519.3519 |
0.416 |
|
| 2011 |
Ho PA, Othus M, Ostronoff F, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG, Blood. 118: 3516-3516. DOI: 10.1182/Blood.V118.21.3516.3516 |
0.367 |
|
| 2011 |
Ostronoff F, Othus M, Ho PA, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report Blood. 118: 2510-2510. DOI: 10.1182/Blood.V118.21.2510.2510 |
0.384 |
|
| 2011 |
Sandhu RK, Lionberger JM, Othus M, Pagel JM, ShannonDorcy K, Hendrie PC, Petersdorf SH, Becker PS, Appelbaum FR, Estey EH. Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not Blood. 118: 1497-1497. DOI: 10.1182/Blood.V118.21.1497.1497 |
0.499 |
|
| 2011 |
Newell LF, Othus M, Walter RB, Petersdorf SH, Chauncey T, Anderson JE, Godwin JE, Kopecky KJ, Appelbaum FR, Estey EH. Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data Blood. 118: 1446-1446. DOI: 10.1182/Blood.V118.21.1446.1446 |
0.304 |
|
| 2010 |
Othus M, Moon J, Margolin K. Melanoma's deadly march to the brain: by what route, and can it be stopped? Cancer. 117: 1560-3. PMID 21472703 DOI: 10.1002/Cncr.25716 |
0.325 |
|
| 2010 |
Caglar HB, Othus M, Allen AM. Esophagus in-field: A new predictor for esophagitis Radiotherapy and Oncology. 97: 48-53. PMID 20832884 DOI: 10.1016/J.Radonc.2010.07.024 |
0.379 |
|
| 2010 |
Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 116: 2224-8. PMID 20562328 DOI: 10.1182/Blood-2010-02-270330 |
0.482 |
|
| 2010 |
Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. British Journal of Haematology. 148: 217-25. PMID 19804455 DOI: 10.1111/J.1365-2141.2009.07917.X |
0.487 |
|
| 2010 |
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian H, Estey EH. Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment Blood. 116: 2191-2191. DOI: 10.1182/Blood.V116.21.2191.2191 |
0.4 |
|
| 2010 |
Franklin AR, Alonzo TA, Gerbing RB, Donohue K, Othus M, Horan J, Estey EH, Larson RA, Woods WG. Outcome of Adolescents and Young Adults (AYAs) with Non-M3 Acute Myeloid Leukemia (AML) Treated on Children's Oncology Group (COG) Trials Compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) Trials Blood. 116: 183-183. DOI: 10.1182/Blood.V116.21.183.183 |
0.451 |
|
| 2010 |
Xie B, Othus M, Medeiros BC, Fang M, Appelbaum FR, Estey EH. Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype. Blood. 116: 1671-1671. DOI: 10.1182/Blood.V116.21.1671.1671 |
0.431 |
|
| 2010 |
Roshal M, Chien S, Othus M, Wood B, Appelbaum FR, Estey EH, Papayannopoulou T, Becker PS. CD38 Status of CD34+ Myeloblasts, but Not Side Population (SP) Frequency, Predicts Initial Response to Induction Therapy In Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood. 116: 1056-1056. DOI: 10.1182/Blood.V116.21.1056.1056 |
0.368 |
|
| 2009 |
Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer. 115: 4156-66. PMID 19551884 DOI: 10.1002/Cncr.24492 |
0.308 |
|
| 2008 |
Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddad RI, Bertagnolli MM. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.). 1: 339-48. PMID 19138978 DOI: 10.1158/1940-6207.Capr-07-0003 |
0.368 |
|
| 2008 |
Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 72: 1110-8. PMID 18468812 DOI: 10.1016/J.Ijrobp.2008.02.048 |
0.31 |
|
| Show low-probability matches. |